Research & Development
Scleroderma treatment by Certa Therapeutics granted US FDA fast track
FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
Fasenra could initiate remission in patients with EGPA, study finds
MANDARA Phase III data highlights remission as an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with monthly subcutaneous injections of Fasenra
SGD Pharma awarded 2024 gold EcoVadis rating
SGD Pharma’s sustainability rating of 77 puts the business in the 98th percentile for manufacturers of glass and glass products
Does CBD really harm the liver?
With the exception of certain approved drugs such, as Epidiolex and Sativex, the US Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) have voiced...
Curia appoints Steve Lavezoli as Vice President, Biologics
Curia, a leading contract research, development and manufacturing organisation, has appointed Steve Lavezoli as Vice President of Biologics
Manufacturing Chemist Webinar Roundtables Series - Oral Dosage Manufacturing
5 March 2024 | Webinar | 15:00 GMT
Several large Indian pharma companies under US FDA scrutiny
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Natco shows there is more to Indian pharma than generics
Company is establishing a solid platform for rapid growth
Natco Pharma wins US patent case against Teva
Ruling by US Court of Appeals is a major relief to the Indian company
Natco Pharma launches generic sofosbuvir in Nepal
Natco becomes the first Indian company to launch the drug after signing a voluntary licence with Gilead Sciences
Intellectual property battles rage on
Spate of cases filed recently shows that patent battles are heating up
You need to be a subscriber to read this article.
to find out more.
What future for branded drugs in India?
A landmark patent ruling against Novartis by the Supreme Court in India could lead branded drug manufacturers to review their strategies. Asia correspondent A Nair looks at the implications